Atara Biotherapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 8.01 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 80.40M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Details
| Name | Atara Biotherapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 10 |
| Founded | 2012 |
| Ipo Date | 2014-10-16 |
| Ceo | Anhco Nguyen |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US0465132068 |
| Cusip | 046513206 |
| Cik | 0001604464 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Anhco Nguyen Ph.D. | President, Chief Executive Officer and Director |
| Kevin G. Sarney CPA | Interim Chief Financial Officer |
| Jim Sesic | Senior Vice President of Regulatory Affairs |
Contact
| Address | 1280 Rancho Conejo Blvd, Thousand Oaks, California 91320, United States |
| Phone | 805 623 4211 |
| Website | https://www.atarabio.com |